Vascular Tissue Neoplasm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major vascular tissue neoplasm markets are expected to exhibit a CAGR of 3.89% during 2024-2034.
The vascular tissue neoplasm market has been comprehensively analyzed in IMARC's new report titled "Vascular Tissue Neoplasm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vascular tissue neoplasm refers to a tumor that originates from the body's vascular system, which includes the blood vessels (arteries, veins, and capillaries) and the lymphatic system. These tumors might be benign or malignant in nature. Benign neoplasms include hemangiomas, which are commonly found in the skin and are more prevalent in infants and young children. On the other hand, malignant vascular neoplasms, known as angiosarcomas, are aggressive cancers that can arise from blood vessel walls. These tumors are relatively rare but can occur in various body parts, such as the soft tissues, liver, or breast. Some common symptoms of the ailment include red or purple skin growths, pain, discomfort, ulceration, fatigue, visible mass or swelling, weakness, unexplained weight loss, etc. The diagnosis of this illness is mainly based on the patient's characteristics, findings, medical history, and physical exam. A healthcare provider may also perform angiography, that uses a dye to help in visualizing the blood vessels and identifying blood flow in the tumor. Furthermore, a biopsy may be conducted to evaluate and diagnose abnormalities in the tissue.
The increasing cases of genetic mutations or alterations that can lead to uncontrolled cell growth and division, resulting in the development of tumors, are primarily driving the vascular tissue neoplasm market. In addition to this, the rising incidences of immune system disorders, in which the body may not effectively recognize or eliminate cancerous cells, are also creating a positive outlook for the market. Moreover, the widespread adoption of radiofrequency ablation techniques, owing to their various advantages, like reduced trauma, faster recovery times, and potentially shorter hospital stays compared to traditional surgical approaches, is further bolstering the market growth. Apart from this, the inflating demand for sclerotherapy, since it involves injecting a therapeutic solution directly into the tumor, causing it to shrink and eventually be absorbed by the body, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies, which aim to block specific molecular markers or pathways that are involved in the tumor's development, is expected to drive the vascular tissue neoplasm market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the vascular tissue neoplasm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vascular tissue neoplasm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vascular tissue neoplasm market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the vascular tissue neoplasm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the vascular tissue neoplasm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current vascular tissue neoplasm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the vascular tissue neoplasm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the vascular tissue neoplasm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the vascular tissue neoplasm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of vascular tissue neoplasm across the seven major markets?
What is the number of prevalent cases (2018-2034) of vascular tissue neoplasm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of vascular tissue neoplasm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with vascular tissue neoplasm across the seven major markets?
What is the size of the vascular tissue neoplasm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of vascular tissue neoplasm?
What will be the growth rate of patients across the seven major markets?
Vascular Tissue Neoplasm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for vascular tissue neoplasm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vascular tissue neoplasm market?
What are the key regulatory events related to the vascular tissue neoplasm market?
What is the structure of clinical trial landscape by status related to the vascular tissue neoplasm market?
What is the structure of clinical trial landscape by phase related to the vascular tissue neoplasm market?
What is the structure of clinical trial landscape by route of administration related to the vascular tissue neoplasm market?
The vascular tissue neoplasm market has been comprehensively analyzed in IMARC's new report titled "Vascular Tissue Neoplasm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vascular tissue neoplasm refers to a tumor that originates from the body's vascular system, which includes the blood vessels (arteries, veins, and capillaries) and the lymphatic system. These tumors might be benign or malignant in nature. Benign neoplasms include hemangiomas, which are commonly found in the skin and are more prevalent in infants and young children. On the other hand, malignant vascular neoplasms, known as angiosarcomas, are aggressive cancers that can arise from blood vessel walls. These tumors are relatively rare but can occur in various body parts, such as the soft tissues, liver, or breast. Some common symptoms of the ailment include red or purple skin growths, pain, discomfort, ulceration, fatigue, visible mass or swelling, weakness, unexplained weight loss, etc. The diagnosis of this illness is mainly based on the patient's characteristics, findings, medical history, and physical exam. A healthcare provider may also perform angiography, that uses a dye to help in visualizing the blood vessels and identifying blood flow in the tumor. Furthermore, a biopsy may be conducted to evaluate and diagnose abnormalities in the tissue.
The increasing cases of genetic mutations or alterations that can lead to uncontrolled cell growth and division, resulting in the development of tumors, are primarily driving the vascular tissue neoplasm market. In addition to this, the rising incidences of immune system disorders, in which the body may not effectively recognize or eliminate cancerous cells, are also creating a positive outlook for the market. Moreover, the widespread adoption of radiofrequency ablation techniques, owing to their various advantages, like reduced trauma, faster recovery times, and potentially shorter hospital stays compared to traditional surgical approaches, is further bolstering the market growth. Apart from this, the inflating demand for sclerotherapy, since it involves injecting a therapeutic solution directly into the tumor, causing it to shrink and eventually be absorbed by the body, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies, which aim to block specific molecular markers or pathways that are involved in the tumor's development, is expected to drive the vascular tissue neoplasm market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the vascular tissue neoplasm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vascular tissue neoplasm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vascular tissue neoplasm market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the vascular tissue neoplasm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the vascular tissue neoplasm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current vascular tissue neoplasm marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the vascular tissue neoplasm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the vascular tissue neoplasm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the vascular tissue neoplasm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of vascular tissue neoplasm across the seven major markets?
What is the number of prevalent cases (2018-2034) of vascular tissue neoplasm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of vascular tissue neoplasm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with vascular tissue neoplasm across the seven major markets?
What is the size of the vascular tissue neoplasm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of vascular tissue neoplasm?
What will be the growth rate of patients across the seven major markets?
Vascular Tissue Neoplasm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for vascular tissue neoplasm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vascular tissue neoplasm market?
What are the key regulatory events related to the vascular tissue neoplasm market?
What is the structure of clinical trial landscape by status related to the vascular tissue neoplasm market?
What is the structure of clinical trial landscape by phase related to the vascular tissue neoplasm market?
What is the structure of clinical trial landscape by route of administration related to the vascular tissue neoplasm market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VASCULAR TISSUE NEOPLASM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VASCULAR TISSUE NEOPLASM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VASCULAR TISSUE NEOPLASM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 VASCULAR TISSUE NEOPLASM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VASCULAR TISSUE NEOPLASM - UNMET NEEDS
10 VASCULAR TISSUE NEOPLASM - KEY ENDPOINTS OF TREATMENT
11 VASCULAR TISSUE NEOPLASM - MARKETED PRODUCTS
11.1 List of Vascular Tissue Neoplasm Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 VASCULAR TISSUE NEOPLASM - PIPELINE DRUGS
12.1 List of Vascular Tissue Neoplasm Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VASCULAR TISSUE NEOPLASM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VASCULAR TISSUE NEOPLASM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VASCULAR TISSUE NEOPLASM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Vascular Tissue Neoplasm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Vascular Tissue Neoplasm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Vascular Tissue Neoplasm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Vascular Tissue Neoplasm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Vascular Tissue Neoplasm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Vascular Tissue Neoplasm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Vascular Tissue Neoplasm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Vascular Tissue Neoplasm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
16 VASCULAR TISSUE NEOPLASM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VASCULAR TISSUE NEOPLASM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VASCULAR TISSUE NEOPLASM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VASCULAR TISSUE NEOPLASM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VASCULAR TISSUE NEOPLASM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VASCULAR TISSUE NEOPLASM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 VASCULAR TISSUE NEOPLASM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VASCULAR TISSUE NEOPLASM - UNMET NEEDS
10 VASCULAR TISSUE NEOPLASM - KEY ENDPOINTS OF TREATMENT
11 VASCULAR TISSUE NEOPLASM - MARKETED PRODUCTS
11.1 List of Vascular Tissue Neoplasm Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 VASCULAR TISSUE NEOPLASM - PIPELINE DRUGS
12.1 List of Vascular Tissue Neoplasm Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VASCULAR TISSUE NEOPLASM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VASCULAR TISSUE NEOPLASM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VASCULAR TISSUE NEOPLASM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Vascular Tissue Neoplasm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Vascular Tissue Neoplasm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Vascular Tissue Neoplasm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Vascular Tissue Neoplasm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Vascular Tissue Neoplasm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Vascular Tissue Neoplasm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Vascular Tissue Neoplasm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Vascular Tissue Neoplasm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Vascular Tissue Neoplasm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Vascular Tissue Neoplasm - Access and Reimbursement Overview
16 VASCULAR TISSUE NEOPLASM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VASCULAR TISSUE NEOPLASM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VASCULAR TISSUE NEOPLASM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
